2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The failure to undergo remyelination is a critical impediment to recovery in multiple sclerosis. Chondroitin sulfate proteoglycans (CSPGs) accumulate at demyelinating lesions creating a nonpermissive environment that impairs axon regeneration and remyelination. Here, we reveal a new role for 2-arachidonoylglycerol (2-AG), the major CNS endocannabinoid, in the modulation of CSPGs deposition in a progressive model of multiple sclerosis, the Theiler9s murine encephalomyelitis virus-induced demyelinating disease. Treatment with a potent reversible inhibitor of the enzyme monoacylglycerol lipase, which accounts for 85% of the 2-AG degradation in the mouse CNS, modulates neuroinflammation and reduces CSPGs accumulation and astrogliosis around demyelinated lesions in the spinal cord of Theiler9s murine encephalomyelitis virus-infected mice. Inhibition of 2-AG hydrolysis augments the number of mature oligodendrocytes and increases MBP, leading to remyelination and functional recovery of mice. Our findings establish a mechanism for 2-AG promotion of remyelination with implications in axonal repair in CNS demyelinating pathologies. SIGNIFICANCE STATEMENT The deposition of chondroitin sulfate proteoglycans contributes to the failure in remyelination associated with multiple sclerosis. Here we unveil a new role for 2-arachidonoylglycerol, the major CNS endocannabinoid, in the modulation of chondroitin sulfate proteoglycan accumulation in Theiler9s murine encephalomyelitis virus-induced demyelinating disease. The treatment during the chronic phase with a potent reversible inhibitor of the enzyme monoacylglycerol lipase, which accounts for 85% of the 2-arachidonoylglycerol degradation in the mouse CNS, modulates neuroinflammation and reduces chondroitin sulfate proteoglycan deposition around demyelinated lesions in the spinal cord of Theiler9s murine encephalomyelitis virus-infected mice. The increased 2-arachidonoylglycerol tone promotes remyelination in a model of progressive multiple sclerosis ameliorating motor dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991 · cited 2×
“, 2012); but as the disease progresses, remyelination becomes less efficient (Chang et al., 2002; Franklin, 2002; Goldschmidt et al., 2009) and the patients’ disability augments.”
BackgroundOrigin of oligodendrocytes in the subventricular zone of the adult brain
Menn, B., Garcia-Verdugo, J. M., Yaschine, C., Gonzalez-Perez, O., Rowitch, D., & Alvarez-Buylla, A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1299-06.2006 · Cited by 972 · cited 1×
“In demyelinating pathologies, most remyelinating oligodendrocytes are derived from the distant parenchyma (Polito and Reynolds, 2005), although neurogenic niches may also contribute to remyelination (Nait-Oumesmar et al., 1999; PicardRiera et al., 2002; Menn et al., 2006; Mecha et al., 2013).”
BackgroundFrischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728 · cited 2×
“Demyelinated areas develop reactive astroglial scars (Frischer et al., 2015) that express and organize extracellular matrix proteins and chondroitin sulfate proteoglycans (CSPGs) that accumulates impeding neuronal growth and remyelination in MS (Sobel and Ahmed, 2001; Back et al.”
BackgroundHyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation
Back, S. A., Tuohy, T. M. F., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N. L., Banine, F., Liu, Y., Chang, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1279 · Cited by 612 · cited 2×
“, 2015) that express and organize extracellular matrix proteins and chondroitin sulfate proteoglycans (CSPGs) that accumulates impeding neuronal growth and remyelination in MS (Sobel and Ahmed, 2001; Back et al., 2005; Chang et al., 2012).”
BackgroundGaltrey, C. M., & Fawcett, J. W. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.09.006 · Cited by 575 · cited 1×
“A basal level of CSPGs production is necessary to maintain the extracellular matrix in a state that ensures synaptic stabilization and plasticity (Carulli et al., 2006; Galtrey and Fawcett, 2007).”
BackgroundNait‐Oumesmar, B., Decker, L., Lachapelle, F., Avellana‐Adalid, V., Bachelin, C., & Van Evercooren, A. B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00873.x · Cited by 560 · cited 1×
“In demyelinating pathologies, most remyelinating oligodendrocytes are derived from the distant parenchyma (Polito and Reynolds, 2005), although neurogenic niches may also contribute to remyelination (Nait-Oumesmar et al., 1999; PicardRiera et al., 2002; Menn et al., 2006; Mecha et al., 2013).”
BackgroundModulation of the proteoglycan receptor PTPσ promotes recovery after spinal cord injury
Lang, B. T., Cregg, J. M., DePaul, M. A., Tran, A. P., Xu, K., Dyck, S. M., Madalena, K. M., Brown, B. P., Weng, Y.-L., Li, S., et al. (2015) · Nature · doi:10.1038/nature13974 · Cited by 465
Remyelination capacity of the MS brain decreases with disease chronicity
Goldschmidt, T., Antel, J., König, F. B., Brück, W., & Kuhlmann, T. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a8260a · Cited by 411 · cited 1×
“In MS, repair and remyelination occurs spontaneously in shadow plaques (Chang et al., 2012); but as the disease progresses, remyelination becomes less efficient (Chang et al., 2002; Franklin, 2002; Goldschmidt et al., 2009) and the patients’ disability augments.”
BackgroundCarulli, D., Rhodes, K. E., Brown, D. J., Bonnert, T. P., Pollack, S. J., Oliver, K., Strata, P., & Fawcett, J. W. (2006) · Journal of Comparative Neurology · doi:10.1002/cne.20822 · Cited by 341
Cortical remyelination: A new target for repair therapies in multiple sclerosis
Chang, A., Staugaitis, S. M., Dutta, R., Batt, C. E., Easley, K. E., Chomyk, A. M., Yong, V. W., Fox, R. J., Kidd, G. J., & Trapp, B. D. (2012) · Annals of Neurology · doi:10.1002/ana.23693 · Cited by 216 · cited 4×
“In MS, repair and remyelination occurs spontaneously in shadow plaques (Chang et al., 2012); but as the disease progresses, remyelination becomes less efficient (Chang et al.”
BackgroundInfluentialMecha, M., Torrao, A. S., Mestre, L., Carrillo-Salinas, F. J., Mechoulam, R., & Guaza, C. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.71 · Cited by 140
Self-citationA Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis
Hernández‐Torres, G., Cipriano, M., Hedén, E., Björklund, E., Canales, Á., Zian, D., Feliú, A., Mecha, M., Guaza, C., Fowler, C. J., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201407807 · Cited by 125 · cited 9×
“Another group of animals were treated with UCM03025, an inhibitor of 2-AG degradation (Department of Organic Chemistry, Universidad Complutense de Madrid) at a dose of 5 mg/kg intraperitoneally on the basis of previous studies (Hernández-Torres et al., 2014) once daily for 10 consecutive days.”
BackgroundMethodInfluentialSelf-citationBernal-Chico, A., Canedo, M., Manterola, A., Victoria Sánchez-Gómez, M., Pérez-Samartín, A., Rodríguez-Puertas, R., Matute, C., & Mato, S. (2015) · Glia · doi:10.1002/glia.22742 · Cited by 87 · cited 1×
“A basal level of CSPGs production is necessary to maintain the extracellular matrix in a state that ensures synaptic stabilization and plasticity (Carulli et al., 2006; Galtrey and Fawcett, 2007).”
Background
Cited by
Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
The extracellular matrix as modifier of neuroinflammation and remyelination in multiple sclerosis
Ghorbani, S., & Yong, V. W. (2021) · Brain · doi:10.1093/brain/awab059 · Cited by 183
“Recently, reduced CSPG accumulation and enhanced oligodendrocyte differentiation have been shown after targeting the endocannabinoid system using 2-arachidonoylglycerol (2-AG).(165) As these compounds can affect CSPG synthesis throughout the body, developing CNS-targeted treatment is necessary to avoid potential off-t…”
BackgroundCalina, D., Buga, A. M., Mitroi, M., Buha, A., Caruntu, C., Scheau, C., Bouyahya, A., El Omari, N., El Menyiy, N., & Docea, A. O. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082395 · Cited by 65
“The mechanisms through which cannabinoids decrease motor disability in MS murine models are diverse: decreasing the neuroinflammation [61,62,64,66,67,70,72–78,80–82,85], increasing anti-inflammatory cytokines [66], decreasing cell proliferation [66], increasing remyelination and axonal protection [68,86], decreasing d…”
BackgroundMethodThe endocannabinoid 2-AG enhances spontaneous remyelination by targeting microglia
Mecha, M., Yanguas-Casás, N., Feliú, A., Mestre, L., Carrillo-Salinas, F., Azcoitia, I., Yong, V. W., & Guaza, C. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.12.013 · Cited by 47
“…increased endogenous 2-AG tone associated with the inhibition of the MAGL enzyme (which drives 2-AG degradation) exerts therapeutic effects, promoting remyelination in the spinal cord of TMEV-IDD mice (Feliú et al., 2017) and preventing demyelination in the EAE model (Bernal-Chico et al., 2015).”
Self-citationSpatially Resolved Mapping of Monoacylglycerol Lipase Activity in the Brain
van der Vliet, D., Klinkenberg, A. X. Y., Platte, R., Higgins, K., Prokop, S., Huizenga, M. C. W., Kraaijevanger, L., van Egmond, N., Straub, V. M., Kole, M. H. P., et al. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00638 · Cited by 4
Metadata
- Authors
- Feliú, A., Bonilla del Río, I., Carrillo-Salinas, F. J., Hernández-Torres, G., Mestre, L., Puente, N., Ortega-Gutiérrez, S., López-Rodríguez, M. L., Grandes, P., Mecha, M., & Guaza, C.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2017-07-27
- Volume
- 37
- Issue
- 35
- Pages
- 8385-8398
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2740917237
- Cited by
- 68
- References
- 13
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.